Athena Heart [310] [LATEST]

: Dronedarone significantly reduced the primary composite endpoint of first cardiovascular hospitalization or death by 24% compared to a placebo.

: Conduct regular ECGs to monitor for potential proarrhythmic effects or excessive QT prolongation.

: Periodic testing is recommended due to reported cases of liver injury. ATHENA HEART [310]

The official FDA label outlines critical safety measures based on ATHENA data: :

Patients with paroxysmal or persistent AF or AFL who are in sinus rhythm or who will be cardioverted. The official FDA label outlines critical safety measures

: Classified as Category X ; it may cause fetal harm and should not be used by pregnant women. Drug Interactions :

: Do not use in patients who cannot or will not be converted to sinus rhythm. The ATHENA trial was a landmark study that

The ATHENA trial was a landmark study that evaluated the efficacy of dronedarone in reducing cardiovascular hospitalizations or death.